The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis

Abstract Background Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without a fourth drug, have been shown to be as...

Celý popis

Podrobná bibliografia

Vydané v:	Clinical infectious diseases Ročník 78; číslo 3; s. 730 - 741
Hlavní autori:	Hasan, Tasnim, Medcalf, Ellie, Nyang'wa, Bern-Thomas, Egizi, Erica, Berry, Catherine, Dodd, Matthew, Foraida, Salah, Gegia, Medea, Li, Mengchun, Mirzayev, Fuad, Morgan, Hannah, Motta, Ilaria, Nguyen, Linh, Schumacher, Samuel, Schlub, Tim, Fox, Greg
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	US Oxford University Press 20.03.2024
Predmet:	Antitubercular Agents - adverse effects Diarylquinolines - therapeutic use Humans Linezolid - adverse effects Nitroimidazoles Randomized Controlled Trials as Topic Rifampin - pharmacology Tuberculosis - drug therapy Tuberculosis, Multidrug-Resistant - drug therapy severe adverse events linezolid multidrug-resistant tuberculosis BPaL
ISSN:	1058-4838, 1537-6591, 1537-6591
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!